Cargando…

Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer

BACKGROUND: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer. METHODS: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on CA125 levels at baseline and 3 months, patients we...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Digant, Lammersfeld, Carolyn A, Vashi, Pankaj G, Braun, Donald P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959041/
https://www.ncbi.nlm.nih.gov/pubmed/20939881
http://dx.doi.org/10.1186/1757-2215-3-22
_version_ 1782188426076880896
author Gupta, Digant
Lammersfeld, Carolyn A
Vashi, Pankaj G
Braun, Donald P
author_facet Gupta, Digant
Lammersfeld, Carolyn A
Vashi, Pankaj G
Braun, Donald P
author_sort Gupta, Digant
collection PubMed
description BACKGROUND: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer. METHODS: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on CA125 levels at baseline and 3 months, patients were classified into 4 groups: 1) Normal (0-35 U/ml) at baseline and three months; 2) High (>35 U/ml) at baseline, normal at three months; 3) Normal at baseline, high at 3 months; 4) High at baseline and three months. Kaplan Meier method was used to calculate survival across the 4 categories. RESULTS: Of 170 patients, 36 were newly diagnosed while 134 had received prior treatment. 25 had stage I disease at diagnosis, 15 stage II, 106 stage III and 14 stage IV. The median age at presentation was 54.2 years (range 23.1 - 82.5 years). At baseline, 31 patients had normal (0-35 U/ml) serum CA125 levels while 139 had high (>35 U/ml) levels. At 3 months, 59 had normal while 111 had high levels. Patients with a reduced CA125 at 3 months had a significantly better survival than those with increased CA125 at 3 months. Patients with normal values of CA125 at both baseline and 3 months had the best overall survival. CONCLUSIONS: These data show that reduction in CA125 after 3 months of therapy is associated with better overall survival in ovarian cancer. Patients without a significant decline in CA125 after 3 months of therapy have a particularly poor prognosis.
format Text
id pubmed-2959041
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29590412010-10-22 Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer Gupta, Digant Lammersfeld, Carolyn A Vashi, Pankaj G Braun, Donald P J Ovarian Res Research BACKGROUND: We investigated the prognostic impact of changes in serum CA125 levels during the first 3 months of therapy in ovarian cancer. METHODS: A case series of 170 ovarian cancer patients treated at Cancer Treatment Centers of America. Based on CA125 levels at baseline and 3 months, patients were classified into 4 groups: 1) Normal (0-35 U/ml) at baseline and three months; 2) High (>35 U/ml) at baseline, normal at three months; 3) Normal at baseline, high at 3 months; 4) High at baseline and three months. Kaplan Meier method was used to calculate survival across the 4 categories. RESULTS: Of 170 patients, 36 were newly diagnosed while 134 had received prior treatment. 25 had stage I disease at diagnosis, 15 stage II, 106 stage III and 14 stage IV. The median age at presentation was 54.2 years (range 23.1 - 82.5 years). At baseline, 31 patients had normal (0-35 U/ml) serum CA125 levels while 139 had high (>35 U/ml) levels. At 3 months, 59 had normal while 111 had high levels. Patients with a reduced CA125 at 3 months had a significantly better survival than those with increased CA125 at 3 months. Patients with normal values of CA125 at both baseline and 3 months had the best overall survival. CONCLUSIONS: These data show that reduction in CA125 after 3 months of therapy is associated with better overall survival in ovarian cancer. Patients without a significant decline in CA125 after 3 months of therapy have a particularly poor prognosis. BioMed Central 2010-10-12 /pmc/articles/PMC2959041/ /pubmed/20939881 http://dx.doi.org/10.1186/1757-2215-3-22 Text en Copyright ©2010 Gupta et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Gupta, Digant
Lammersfeld, Carolyn A
Vashi, Pankaj G
Braun, Donald P
Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
title Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
title_full Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
title_fullStr Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
title_full_unstemmed Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
title_short Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer
title_sort longitudinal monitoring of ca125 levels provides additional information about survival in ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959041/
https://www.ncbi.nlm.nih.gov/pubmed/20939881
http://dx.doi.org/10.1186/1757-2215-3-22
work_keys_str_mv AT guptadigant longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer
AT lammersfeldcarolyna longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer
AT vashipankajg longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer
AT braundonaldp longitudinalmonitoringofca125levelsprovidesadditionalinformationaboutsurvivalinovariancancer